CHILDHOOD ABSENCE EPILEPSY: RX, PK-PD-PHARMACOGENETICS

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 具体目标1a：使用无失败试验设计，确定乙琥胺（ETX）、拉莫三嗪（LTG）或丙戊酸（VPA）是否是儿童失神癫痫（CAE）儿童受试者最有效的初始单药治疗，CAE定义为随时间推移癫痫发作控制可能性最大且治疗限制性副作用风险最低的抗癫痫药物（AED）。 具体目标1b：明确并对比ETX、LTG和VPA单药治疗对CAE儿童认知（尤其是注意力）、行为和生活质量的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Specific Aim 1a: To determine whether ethosuximide (ETX), lamotrigine (LTG) or valproic acid (VPA) is the most effective initial monotherapy for pediatric subjects with childhood absence epilepsy (CAE), defined as the antiepileptic drug (AED) with the greatest likelihood of seizure control and lowest risk of treatment limiting side effects over time, using a freedom from failure trial design. Specific Aim 1b: To define and contrast the effects of ETX, LTG, and VPA monotherapy on cognition (especially attention), behavior and quality of life in children with CAE.